HOLLOW FIBER BIOREACTOR WITH IMPROVED OXYGENATION

具有改善氧合作用的中空纤维生物反应器

• 批准号: 3498404
• 负责人: Bruce Amiot
• 金额: $ 4.98万
• 依托单位: BIOVEST INTERNATIONAL, INC.
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-09-30 至 1990-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3498404
• 关键词: hollow fiber separation technique; hybridomas; laboratory mouse; oxygen transport; respiratory oxygenation; tissue /cell culture

Recombinant research has facilitated the in vitro production of mmmlian cell secreted products. These products are used in the invitro and in vivo diagnostic and therapeutic setting. Products that have been approved or are in the appr-oval process have projected market needs on the order of 100 kilogram per year. The requirerwnts of large quantities, like this, will be difficult to produce using today's state of the art cell culture methods. A new hollow fiber bioreactor has been developed that can meet these production needs in a cost effective manner. The device has all of the advantages of hollow fiber cell culture; high cell density, low culture volumes, high product concentration and purity, low serum/growth factor requirement and compact size. The bioreactor is a novel design, that is easily manufacttured without large investments in capital equipment and is linearly scalable. The device can transfer oxygen at a rate of 196 mM/hour/liter (K1a=3920 hrs=1). The proposed Phase I research objective is to gbenerate the data required to optimize the design of the commercial bioreactor. This bioreactyor will allow very large scale mammalian cell with less space and reduced equipment costs when compared to today's state of the art cell culture methods. This research will lead to Phase II development of the commercial bioreactor and lay the groundwork for improved cell culture instrumentation development.

重组研究促进了mmmlian的体外生产 细胞分泌产物。这些产品用于体外和 体内诊断和治疗环境。减让产品 已批准或正在批准过程中的公司已预测市场需求， 每年大约100公斤。大的需求 像这样的数量，将很难生产使用今天的状态， 本领域的细胞培养方法。 一种新的中空纤维生物反应器已经开发出来，可以满足这些 以成本效益的方式生产。该设备具有所有 中空纤维细胞培养的优点：高细胞密度，低培养 体积、高产品浓度和纯度、低血清/生长因子 要求和紧凑的尺寸。 该生物反应器是一种新颖的设计，其易于制造，而无需 在资本设备上的大量投资，并且是线性可扩展的。的 装置可以以196 mM/小时/升的速率（K1 a =3920 hrs=1）。 拟议的第一阶段研究目标是生成数据 优化商业生物反应器的设计。这 生物反应器将允许具有更小空间的非常大规模的哺乳动物细胞 与当今的技术水平相比， 细胞培养方法。这项研究将导致第二阶段的发展， 商业化的生物反应器，并为改进细胞 培养仪器的发展。